Sunitinib paves the way for targeted therapies in neuroendocrine tumors

Targeted Oncology

Volumn 4, Issue 4, 2009, Pages 253-254

  Raymond, Eric ^a   Faivre, Sandrine ^a   Hammel, Pascal ^a   Ruszniewski, Philippe ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

Angiogenesis; Pancreatic carcinoma, VEGF; Sunitinib; VEGFR, targeted therapy

Indexed keywords

IMATINIB; PLACEBO; SUNITINIB;

ANTINEOPLASTIC ACTIVITY; CANCER CONTROL; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GROWTH INHIBITION; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; NEUROENDOCRINE TUMOR; NEUTROPENIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; TREATMENT RESPONSE; TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOID TUMOR; CELL LINE, TUMOR; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; HUMANS; INDOLES; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MELPHALAN; NEOVASCULARIZATION, PATHOLOGIC; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PROCARBAZINE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; PYRROLES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL; VINBLASTINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 72449167379     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-009-0130-0     Document Type: Review

References (12)

1. S Faivre C Delbaldo K Vera C Robert S Lozahic N Lassau, et al. 2006 Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer J Clin Oncol 24 25 35 10.1200/JCO.2005.02.2194 1:CAS:528:DC%2BD28Xot1ChtQ%3D%3D 16314617 (Pubitemid 46630490)
2. S Faivre S Djelloul E Raymond 2006 New paradigms in anticancer therapy: targeting multiple signalling pathways with kinase inhibitors Semin Oncol 33 407 420 10.1053/j.seminoncol.2006.04.005 1:CAS:528:DC%2BD28XpsVersb4%3D 16890796 (Pubitemid 44142738)
3. S Faivre G Demetri W Sargent E Raymond 2007 Molecular basis for sunitinib efficacy and future clinical development Nat Rev Drug Discov 6 9 734 745 10.1038/nrd2380 1:CAS:528:DC%2BD2sXpslaksL8%3D 17690708 (Pubitemid 47338181)
4. RJ Motzer TE Hutson P Tomczak MD Michaelson RM Bukowski O Rixe, et al. 2007 Sunitinib versus interferon α in metastatic renal-cell carcinoma N Eng. J Med 356 115 124 10.1056/NEJMoa065044 1:CAS:528:DC%2BD2sXksVGqsw%3D%3D (Pubitemid 46089672)
5. GD Demetri AT van Oosterom CR Garrett ME Blackstein MH Shah J Verweij, et al. 2006 Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomized controlled trial Lancet 368 1329 1338 10.1016/S0140-6736(06)69446-4 1:CAS:528:DC%2BD28XhtVOrtL%2FL 17046465 (Pubitemid 44528723)
6. A Couvelard D O'Toole H Turley R Leek A Sauvanet C Degott, et al. 2005 Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression Br J Cancer 92 1 94 101 10.1038/sj.bjc. 6602245 1:CAS:528:DC%2BD2MXhtFSjsr4%3D 15558070 (Pubitemid 40188441)
7. K Pietras D Hanahan 2005 A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer J Clin Oncol 23 939 952 10.1200/JCO.2005.07.093 1:CAS:528:DC%2BD2MXit1Ggu7k%3D 15557593 (Pubitemid 46202314)
8. MH Kulke HJ Lenz NJ Meropol J Posey DP Ryan J Picus, et al. 2008 Activity of sunitinib in patients with advanced neuroendocrine tumors J Clin Oncol 26 20 3403 3410 10.1200/JCO.2007.15.9020 1:CAS:528:DC%2BD1cXpvVWitro%3D 18612155
9. Raymond E, Raoul JL, Niccoli P, Bang Y-J, Borbath Y, Lombard-Bohas C et al (2009) Phase III, randomized, double-blind trial of sunitinib vs placebo in patients with progressive, well-differentiated, malignant pancreatic islet cell tumors. Ann Oncol 20(10): abstract O-008
10. JL Raoul P Niccoli Y-J Bang I Borbath C Lombard-Bohas P Metrakos, et al. 2009 Sunitinib (SU) vs placebo for treatment of progressive, well-differentiated pancreatic islet cell tumours: results of a phase III, randomised, double-blind trial Eur J Cancer Suppl 7 2 361 10.1016/S1359-6349(09)71223-6
11. N Theou-Anton S Faivre C Dreyer E Raymond 2009 Benefit-risk assessment of sunitinib in gastrointestinal stromal tumours and renal cancer Drug Saf 32 9 717 734 10.2165/00002018-200932090-00003 1:CAS:528:DC%2BD1MXht1WhsbvK 19670913
12. JC Yao AT Phan DZ Chang RA Wolff K Hess S Gupta, et al. 2008 Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study J Clin Oncol 26 26 4311 4318 10.1200/JCO.2008.16.7858 18779618